Every corner of the biotech industry is being impacted by the coronavirus pandemic. There will be office interruptions, delays in drug development and clinical trials, extensions of regulatory reviews, and limits on new drug launches. Sales of certain older drugs will drop along with prescriptions. Expect investor and financing challenges, too. What do you need to know about this unprecedented disruption?
STAT senior writers Matthew Herper and Adam Feuerstein discussed all this during our most recent STAT Plus video chat, “Biotech in uncharted territory.”